Cite
HARVARD Citation
Siddiqi, T. et al. (2020). Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies. Leukemia & lymphoma. 61 (2), pp. 309-317. [Online].